Immuno-oncological treatments refer to cancer treatments (drugs) whose purpose is to strengthen the body’s own immune response against cancer. Previously used immunomodulators include interferon, used for the treatment of cancers such as melanoma. The new-generation immuno-oncological treatments are based on a different mechanism. They, too, were first used for the treatment of melanoma. Research data used as the basis for a marketing authorisation have so far been reported for melanoma, lung cancer and kidney cancer. In addition, preliminary research results have been reported, and more extensive studies on a number of other cancers are underway.
Currently, these new-generation immuno-oncological drugs include the CTLA-4 antibody Yervoy® (ipilimumab), the PD-1 antibody Keytruda® (pembrolizumab) and the PD-1 antibody Opdivo® (nivolumab). In addition, there are many therapies that are still being studied and have not yet been launched on the market. Oncolytic viruses constitute another group of immuno-oncological therapies. The first of these therapies to achieve a marketing authorisation is Imlygic™ (talimogene laherparepvec).
Docrates a forerunner in immuno-oncological treatments
Docrates Cancer Center started immuno-oncological treatments already in March 2015, using pembrolizumab. After this, we have also started nivolumab treatments. In addition, we have started or are about to start a number of drug trials with immuno-oncological treatments. You will find more information about our ongoing clinical trials here. Docrates has gained experience in oncolytic adenovirus research and treatments since 2007. Docrates was the first European centre with a certification for oncolytic herpes virus treatments and Imlygic treatments.